ReviewBiomaterials research2025
Endothelial Dysfunction in Atherosclerosis: Experimental Models and Therapeutics.
Review in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Vascularized bone organoids: current advances and a biomimetic platform for osteonecrosis of the femoral head.Bone research · 2026Review
- Endothelial cells modulate immune cell responses during atherosclerosis.Trends in immunology · 2026Review
- Unveiling the Molecular Mechanism of 6PPD and 6PPD-Q in Lipid-Metabolism-Related Diseases Through Network Toxicology and Experimental Validation.International journal of molecular sciences · 2026Article
- A Four-Channel Microfluidic Vascular-Wall Chip for Modeling Early Atherosclerosis-Related Endothelial Dysfunction and Evaluating Combined Anti-Inflammatory Treatment.Micromachines · 2026Article
- Macrophage microRNAs integrating lipid metabolism and inflammation: Implications for atherosclerosis.Metabolism open · 2026Review
- Impact of geometric factors and shear stress on endothelial function: Hemodynamic insights from human cerebral arterial bifurcations.Physiological reports · 2026Article
- LRG1 as a Potential Therapeutic Target in Atherosclerosis: Mechanistic Basis and Current Evidence.Cells · 2026Review
- Enhanced Anti-Atherogenic Effects of Epicatechin and Hydroxytyrosol in THP-1 Macrophages: An Integrated In Silico and In Vitro Study.International journal of molecular sciences · 2026Article
- From Cheese Whey to Functional Ingredients: Upcycling Whey Proteins for Cardiovascular and Immunomodulatory Health-Evidence Mapping and Perspectives from Portugal.Foods (Basel, Switzerland) · 2026Review
- Nitric Oxide Signaling in Cardiovascular Physiology and Pathology: Mechanisms, Dysregulation, and Therapeutic Frontiers.International journal of molecular sciences · 2026Review
- Targeting vascular inflammation and endothelial dysfunction with nanobodies: emerging therapeutic strategies for cardiovascular disease.Frontiers in immunology · 2026Review
- AI-driven identification of nutrition-modulated biomarkers and drug targets for cardiovascular therapeutic mechanisms.Frontiers in pharmacology · 2026Review
- Hemodynamics and matrix stiffness shape the pathogenicity of SPP1Frontiers in immunology · 2026Review
- Sphingolipid Metabolism: A Pathological Hub Linking Lipid Dysregulation and Chronic Inflammation in Atherosclerotic Cardiovascular Disease.Journal of inflammation research · 2026Review
- Gut-heart axis at high altitude: a dynamic mediator from hypoxic dysbiosis to adaptive cardioprotection.Frontiers in microbiology · 2026Review
- Mechanisms of mitochondrial dysfunction and protective strategies in skin flap ischemia-reperfusion injury.Frontiers in pharmacology · 2026Review
- Blueberries and Honeysuckle Berries: Anthocyanin-Rich Polyphenols for Vascular Endothelial Health and Cardiovascular Disease Prevention.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a cardiovascular disease that involves complex and multifactorial processes that are instigated from endothelial dysfunctions. In this review, we address endothelial dysfunction in atherosclerosis and the mechanisms, where they are characterized by structural and functional alterations in endothelial cells (ECs), as caused by inflammation, oxidative stress, or disturbed shear stress. In particular interest, we provide a comprehensive overview of the experimental models (in vitro and in vivo) used to investigate endothelial dysfunction, specifically the role of ECs in atherosclerosis. Finally, current therapeutics, for example, pharmacological interventions, cell and gene therapies, and nanomedicine, are introduced, along with emerging technologies for advanced treatment of atherosclerosis. This review will help readers better understand current scientific findings, experimental models, and technologies in an effort to decipher the mechanisms of atherosclerosis and to advance therapeutic interventions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.